

09-12-05

IFW

Docket 17686 (OCU)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: PATRICK M. HUGHES et al.)	Examiner:
Serial Number: 10/826,441)	
Filed: April 15, 2004)	Art Unit: 1645
For: STABILIZED BIODEGRADABLE)	Confirmation No.: 1056
NEUROTOXIN IMPLANT)	Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicant's provide with regard to the patent application entitled STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT, filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: September 7, 2005


Stephen Donovan
Registration Number 33,433


Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246.4026
Fax: 714.246.4249


CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date September 9, 2005, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EL980001055US addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Adriane Giberson
Name of person mailing paper


Signature of person mailing paper

Date: September 9, 2005



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17686 (OCU)	SERIAL NO.: 10/826,441
APPLICANT: Patrick M. Hughes et al.	TITLE: STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT
FILING DATE: April 15, 2004	GROUP: 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	4,853,224	08/01/1989	WONG	424	427	
	AB	4,997,652	03/05/1991	WONG	424	428	
	AC	5,164,188	11/17/1992	WONG	424	428	
	AD	5,378,475	01/03/1995	SMITH et al.	424	473	
	AE	5,443,505	08/22/1995	WONG et al.	623	4	
	AF	6,217,895	04/17/2001	GUO et al.	424	427	
	AG	6,548,078	04/15/2003	GUO et al.	424	423	
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						
	BC						
	BD						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Cheng, Cheng-Kuo et al., <i>Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis</i> , Investigative Ophthalmology & Visual Science, February 1995, Vol. 36, No. 2, pp. 442-453
	CB	Enyedi, Laura B. et al., <i>An intravitreal device providing sustained release of cyclosporine and dexamethasone</i> , Current Eye Research, October 17, 1995, pp. 549-557
	CC	Hainsworth, Dean P. et al., <i>Sustained Release Intravitreal Dexamethasone</i> , Journal of Ocular Pharmacology and Therapeutics, Volume 12, Number 1, 1996, pp. 57-63
	CD	Kochinke, F. et al., <i>Biodegradable Drug Delivery System for Uveitis Treatment</i> , Investigative Ophthalmology & Visual Science, February 15, 1996, Vol. 37, No. 3, 186—B98
	CE	
	CF	
	CG	
	CH	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.